However, FGFR2 signaling in the tumor setting, where FGF2 and FGF7 are likely available from the surrounding microenvironment [30], [32], may establish a paracrine pathway leading to continued cancer cell survival, growth and maintenance of transformation in the presence of EGFR targeted therapies. The gene discussed is FGF2; the disease is neoplasm.